Literature DB >> 26933708

An approach to the young hypertensive patient.

P Mangena, S Saban, K E Hlabyago, B Rayner.   

Abstract

Hypertension is the leading cause of death worldwide. Globally and locally there has been an increase in hypertension in children, adolescents and young adults<40 years of age. In South Africa, the first decade of the millennium saw a doubling of the prevalence rate among adolescents and young adults aged 15-24 years. This increase suggests that an explosion of cerebrovascular disease, cardiovascular disease and chronic kidney disease can be expected in the forthcoming decades. A large part of the increased prevalence can be attributed to lifestyle factors such as diet and physical inactivity, which lead to overweight and obesity. The majority (>90%) of young patients will have essential or primary hypertension, while only a minority (<10%) will have secondary hypertension. We do not recommend an extensive workup for all newly diagnosed young hypertensives, as has been the practice in the past. We propose a rational approach that comprises a history to identify risk factors, an examination that establishes the presence of target-organ damage and identifies clues suggesting secondary hypertension, and a limited set of basic investigations. More specialised tests should be performed only where there is a clinical suspicion that a secondary cause for hypertension exists. There have been no randomised clinical trials on the treatment of hypertension in young patients. Expert opinion advises an initial emphasis on lifestyle modification. This can comprise a diet with reduced salt and refined carbohydrate intake, an exercise programme and management of substance abuse issues. Failure of lifestyle measures or the presence of target-organ damage should prompt the clinician to initiate pharmacotherapy. We recommend referral to a specialist practitioner in cases of resistant hypertension, where there is severe target-organ damage and when a secondary cause is suspected.

Entities:  

Mesh:

Year:  2016        PMID: 26933708     DOI: 10.7196/samj.2016.v106i1.10329

Source DB:  PubMed          Journal:  S Afr Med J


  7 in total

1.  Psychometric properties of the Malay version of the Behavioural Regulation in Exercise Questionnaire (BREQ-3).

Authors:  Shirlie Chai; Yee Cheng Kueh; Najib Majdi Yaacob; Garry Kuan
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

2.  One in five South Africans are multimorbid: An analysis of the 2016 demographic and health survey.

Authors:  Rifqah Abeeda Roomaney; Brian van Wyk; Annibale Cois; Victoria Pillay-van Wyk
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

3.  Anxiety, Stress-Related Factors, and Blood Pressure in Young Adults.

Authors:  Nicola Mucci; Gabriele Giorgi; Stefano De Pasquale Ceratti; Javier Fiz-Pérez; Federico Mucci; Giulio Arcangeli
Journal:  Front Psychol       Date:  2016-10-28

4.  Budget impact analysis of the adoption of new hypertension guidelines in Colombia.

Authors:  Cesar Augusto Guevara-Cuellar; Victoria Eugenia Soto; María Isabel Molina-Echeverry
Journal:  Cost Eff Resour Alloc       Date:  2018-09-25

5.  Antihypertensive prescription among black patients without compelling indications: prescription, effectiveness, quality and cost of medication.

Authors:  Onyinye Onyeka Akunne; Aduragbenro Deborah A Adedapo
Journal:  BMC Health Serv Res       Date:  2019-06-13       Impact factor: 2.655

6.  Page kidney: A rare cause of secondary hypertension.

Authors:  Ilonka Warnich; Mark Nicolaou; Zelia Sofianos; Jacobus A Pienaar; Jacob Varghese
Journal:  SA J Radiol       Date:  2019-09-23

7.  Ethnopharmacological Survey on Treatment of Hypertension by Traditional Healers in Bukavu City, DR Congo.

Authors:  Félicien Mushagalusa Kasali; Christian Ahadi Irenge; Pacifique Murhula Hamuli; Patient Birindwa Mulashe; Delphin Murhula Katabana; Jean De Dieu Mangambu Mokoso; Pius Tshimankinda Mpiana; Justin Ntokamunda Kadima
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-09       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.